Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19GlobeNewsWire • 05/21/25
Invivyd Reports First Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/15/25
Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine EfficacyGlobeNewsWire • 05/14/25
Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor ConferenceGlobeNewsWire • 05/13/25
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for MeaslesGlobeNewsWire • 05/12/25
Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025GlobeNewsWire • 05/08/25
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of DirectorsGlobeNewsWire • 03/26/25
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business HighlightsGlobeNewsWire • 03/20/25
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1GlobeNewsWire • 03/05/25
FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised PatientsBenzinga • 02/24/25
FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised PatientsGlobeNewsWire • 02/24/25
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025GlobeNewsWire • 02/10/25
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A ColdGlobeNewsWire • 02/05/25
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term ProfitabilityGlobeNewsWire • 02/03/25
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised PatientsGlobeNewsWire • 01/27/25
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XECGlobeNewsWire • 01/10/25
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/14/24